Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT07504328
Active, not recruiting Observational

Robson Classification System Monitoring and Auditing Caesrean Section Rates

NCT07504328 · tracked via the Priya Life Science Egypt tracker
Sponsor
Sohag University
Phase
Observational
Started
2026-02-01
Last updated
2026-03-31

Condition(s) studied

Caesrean Section RatesRobson Classification

Investigational drug(s) / intervention(s)

just monitoring and auditing ,so there is no intevention

just monitoring and auditing ,so there is no intevention: just monitoring and auditing ,so there is no intevention

Study summary

Robson Classification System Monitoring and Auditing Caesrean Section Rates

Eligibility

Sex
FEMALE
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * All pregnant women delivering at ≥ 28 weeks gestation. * Singleton or multiple pregnancy. * Cephalic, Breech, or transverse lie. Exclusion Criteria: * Gestational age \< 28 weeks. * Intrauterine fetal demises before admission

Primary outcome measure(s)

  • Change in overall Caesarean section rate — until 1/february/2027
    All eligible deliveries during the study period will be included (total coverage sampling). Collection of baseline data on mode of delivery. Calculation of CS rate and indications. Classification of women retrospectively into Robson groups. Monthly audit meetings to discuss CS indications per Robson group. Data Collection Data will be collected using a structured sheet including: Maternal age Parity Gestational age Onset of labor Fetal presentation Number of fetuses Mode of delivery Indication of CS Robson group Maternal outcome Neonatal outcome

Trial sites (1)

FacilityCityRegionStatus
Sohag University Sohag Egypt

More Sohag University trials in Egypt

Colitis Patterns in Patients With Lower GI Symptoms Starting soon
Zadek Osteotomy for Treatment of Haglund's Syndrome Recruiting
Effects of Dexmedetomidine Combined With Lidocaine Topical Administration on Cough Reflex During Extubation in Thyroidectomy Patient. Active, not recruiting
Toxoplasma Gondii Seroprevalence Among Children With Some Neuropsychiatric Disorders Starting soon
Accuracy of Transabdominal Ultrasound in Predicting Intraperitoneal Adhesions Prior to Laparoscopy Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07504328 on ClinicalTrials.gov ↗ ← All trials in Egypt